NCT02942173View on ClinicalTrials.gov

CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

August 21, 2019

Study Completion Date

August 21, 2020

Conditions
LeukemiaLymphomaMyelodysplastic SyndromesGvHDOpportunistic InfectionsGraft-versus-Host Disease
Interventions
BIOLOGICAL

CD45RA-depleted peripheral blood mononuclear cells

Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells

Trial Locations (1)

117997

Federal Research Center for pediatric hematology, oncology and immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER

NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT | Biotech Hunter | Biotech Hunter